Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2025

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRoger S. McIntyreGSGerard SanacoraDWDavid P. Walling

Discussion

Loading...

Member takes

Overview

Phase Ib trial shows BI 1569912 improves depression scores in adults with MDD, indicating promising safety and efficacy.

Key Points

  • BI 1569912 demonstrated a clinically relevant improvement in depression scores, enhancing potential treatment options.
  • Participants receiving the 20 mg dose showed a 3.4- to 4.9-point improvement in MADRS total score compared to placebo.
  • This randomized, double-blind trial assessed safety and efficacy over 15 days in adults with major depressive disorder.
  • No increase in adverse events or risk of dissociation was observed, supporting further development of BI 1569912.

Cite This Study

McIntyre et al. (2025) studied this question.

synapsesocial.com/papers/68a3688b0a429f797332dca4https://doi.org/10.1002/cpt.70018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials2026 · 1 citations
  2. 2NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials2026
  3. 3Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression2026 · 2 citations
  4. 4Discovery of VU6066098: A Selective and CNS-Penetrant mGlu <sub>2</sub> NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in Rodents2026
  5. 5The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression2026